VRTX
Vertex Pharmaceuticals Inc
$
416.250
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
424.250
Open
414.100
VWAP
417.11
Vol
1.33M
Mkt Cap
105.61B
Low
410.290
Amount
555.58M
EV/EBITDA(TTM)
21.01
Total Shares
258.05M
EV
99.51B
EV/OCF(TTM)
26.77
P/S(TTM)
9.19
Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q2
FY2026Q1
FY2025Q4
3.22B
+8.54%
5.016
+10.97%
3.15B
+13.89%
4.953
+21.99%
3.19B
+9.55%
5.122
+28.69%
Estimates Revision
The market is revising Upward the revenue expectations for Vertex Pharmaceuticals Incorporated (VRTX) for FY2025, with the revenue forecasts being adjusted by 0.17% over the past three months. During the same period, the stock price has changed by 7.93%.
Revenue Estimates for FY2025
Revise Upward
+0.17%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-0.27%
In Past 3 Month
Stock Price
Go Up
+7.93%
In Past 3 Month
25 Analyst Rating
17.59% Upside
Wall Street analysts forecast VRTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VRTX is 489.48 USD with a low forecast of 401.00 USD and a high forecast of 624.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Buy
10 Hold
0 Sell
Moderate Buy
17.59% Upside
Current: 416.250
Low
401.00
Averages
489.48
High
624.00
17.59% Upside
Current: 416.250
Low
401.00
Averages
489.48
High
624.00
Stifel
Hold
downgrade
$455 -> $445
2025-11-04
New
Reason
Stifel
Price Target
$455 -> $445
2025-11-04
New
downgrade
Hold
Reason
Stifel lowered the firm's price target on Vertex Pharmaceuticals to $445 from $455 and keeps a Hold rating on the shares. The commercial business appears to have a more narrow variance on a quarter-to-quarter basis, making Vertex "less of a beat-and-raise story and more one that may be dependent on pipeline for significant upside," the analyst tells investors in a post-earnings note.
RBC Capital
Sector Perform
downgrade
$423 -> $415
2025-11-04
New
Reason
RBC Capital
Price Target
$423 -> $415
2025-11-04
New
downgrade
Sector Perform
Reason
RBC Capital lowered the firm's price target on Vertex Pharmaceuticals to $415 from $423 and keeps a Sector Perform rating on the shares. Compared to Q2, the company registered a more uneventful quarter, the analyst tells investors in a research note. Vertex's cystic fibrosis, CF, franchise remains healthy, though slow launches elsewhere and increased spend underscore intrinsic limitations to operating leverage growth as the company diversifies, the analyst tells investors in a research note.
Barclays
Gena Wang
Equal Weight
maintain
$408 -> $414
2025-11-04
New
Reason
Barclays
Gena Wang
Price Target
$408 -> $414
2025-11-04
New
maintain
Equal Weight
Reason
Barclays analyst Gena Wang raised the firm's price target on Vertex Pharmaceuticals to $414 from $408 and keeps an Equal Weight rating on the shares. The company reported a slight beat in Q3 with a slight raise to the lower end of its revenue guidance, the analyst tells investors in a research note.
BofA
Buy
downgrade
$565 -> $563
2025-10-21
Reason
BofA
Price Target
$565 -> $563
2025-10-21
downgrade
Buy
Reason
BofA lowered the firm's price target on Vertex Pharmaceuticals to $563 from $565 and keeps a Buy rating on the shares. The firm, which expects steady growth for the cystic fibrosis franchise in Q3, remains "bullish" on the strong commercial performance of the CF franchise and multiple shots on goal across the portfolio, the analyst tells investors in a preview.
Leerink
Market Perform -> Outperform
upgrade
$456
2025-09-25
Reason
Leerink
Price Target
$456
2025-09-25
upgrade
Market Perform -> Outperform
Reason
Leerink upgraded Vertex Pharmaceuticals to Outperform from Market Perform with a $456 price target.
Leerink
Leerink
Market Perform -> Outperform
upgrade
$458 -> $456
2025-09-25
Reason
Leerink
Leerink
Price Target
$458 -> $456
2025-09-25
upgrade
Market Perform -> Outperform
Reason
As previously reported, Leerink upgraded Vertex Pharmaceuticals to Outperform from Market Perform with a price target of $456, down from $458. Based upon a MEDACorp Journavx survey, the firm anticipates strong adoption and upward pressure on reset consensus pain revenue expectations in 2026-plus. The company's cystic fibrosis franchise is likely to deliver solid growth, including increasing adoption of Alyftrek, and it appears durable through 2039, Leerink adds. The firm also points out that the company has a rapidly advancing pipeline that is set to diversify its revenue beyond CF, and it anticipates accelerating novel drug newsflow in 2026. Regarding the stock, Vertex shares now trade at a forward price to earnings that hasn't been seen since 2022, Leerink adds.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Vertex Pharmaceuticals Inc (VRTX.O) is 20.65, compared to its 5-year average forward P/E of 187.24. For a more detailed relative valuation and DCF analysis to assess Vertex Pharmaceuticals Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
187.24
Current PE
20.65
Overvalued PE
782.44
Undervalued PE
-407.96
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
22.47
Current EV/EBITDA
15.45
Overvalued EV/EBITDA
46.78
Undervalued EV/EBITDA
-1.84
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
10.66
Current PS
417.00
Overvalued PS
39.49
Undervalued PS
-18.18
Financials
Annual
Quarterly
FY2025Q3
YoY :
+10.99%
3.08B
Total Revenue
FY2025Q3
YoY :
+9.47%
1.24B
Operating Profit
FY2025Q3
YoY :
+3.59%
1.08B
Net Income after Tax
FY2025Q3
YoY :
+4.74%
4.20
EPS - Diluted
FY2025Q3
YoY :
-12.48%
1.14B
Free Cash Flow
FY2025Q3
YoY :
+0.79%
86.52
Gross Profit Margin - %
FY2025Q3
YoY :
-323.82%
28.47
FCF Margin - %
FY2025Q3
YoY :
-6.66%
35.20
Net Margin - %
FY2025Q3
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
102.9K
USD
1
6-9
Months
7.1M
USD
6
0-12
Months
7.2M
USD
11
Bought
0-3
0
0.0
USD
Months
3-6
2
5.8M
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 149.17% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
319.8K
Volume
5
0-12
Months
128.3K
Volume
8
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
4
209.2K
Volume
Months
0-12
2
1.4M
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
16.0K
USD
2
6-9
Months
8.0K
USD
1
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
2
16.0K
USD
Months
6-9
0
0.0
USD
Months
0-12
3
73.0K
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
102.9K
USD
1
6-9
Months
7.1M
USD
6
0-12
Months
7.2M
USD
11
Bought
0-3
0
0.0
USD
Months
3-6
2
5.8M
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
VRTX News & Events
Events Timeline
2025-11-06 (ET)
2025-11-06
14:02:12
FDA Grants Second Round of National Priority Vouchers
2025-11-03 (ET)
2025-11-03
16:04:42
Vertex Pharmaceuticals announces Q3 adjusted EPS of $4.80, surpassing consensus estimate of $4.58.
2025-10-17 (ET)
2025-10-17
09:08:39
Vertex Pharmaceuticals reveals new developments in povetacicept program
Sign Up For More Events
Sign Up For More Events
News
9.5
11-05Yahoo FinancePinnedVertex Pharmaceuticals (VRTX) Achieves Profitability, Countering Negative Perceptions on Earnings Integrity
4.5
11-04BenzingaPalantir Impacts Wall Street as Bitcoin Drops 5%: Market Movers for Tuesday
6.0
11-04BenzingaRBC Capital Keeps Sector Perform Rating for Vertex Pharmaceuticals, Reduces Price Target to $415
Sign Up For More News
People Also Watch
UPS
United Parcel Service Inc
93.600
USD
+0.74%
APP
Applovin Corp
621.360
USD
+0.70%
NKE
Nike Inc
61.890
USD
-0.35%
CB
Chubb Ltd
283.050
USD
-0.07%
ADI
Analog Devices Inc
232.880
USD
-1.32%
DE
Deere & Co
475.380
USD
+0.36%
GILD
Gilead Sciences Inc
123.400
USD
+0.67%
BMY
Bristol-Myers Squibb Co
46.630
USD
+0.34%
LMT
Lockheed Martin Corp
468.920
USD
-0.89%
IBN
ICICI Bank Ltd
29.870
USD
-1.65%
FAQ
What is Vertex Pharmaceuticals Inc (VRTX) stock price today?
The current price of VRTX is 416.25 USD — it has decreased -0.18 % in the last trading day.
What is Vertex Pharmaceuticals Inc (VRTX)'s business?
What is the price predicton of VRTX Stock?
What is Vertex Pharmaceuticals Inc (VRTX)'s revenue for the last quarter?
What is Vertex Pharmaceuticals Inc (VRTX)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Vertex Pharmaceuticals Inc (VRTX)'s fundamentals?
How many employees does Vertex Pharmaceuticals Inc (VRTX). have?